[ad_1]
Andrew Pollard, director of vaccine studies at the University of Oxford, told British lawmakers in parliament that they will present the results of the latest phase of human trials of the vaccine they developed later this year. Pollard said whether the vaccine will work will be largely clear later this year and said policy makers should make a decision on who should get the vaccine first.
However, Polard told a question about the possibility of introducing the vaccine before Christmas: “There is a small chance that it is possible, but I don’t know.”
THE VACCINE CAN BE DISTRIBUTED AT THE END OF THE YEAR
On the other hand, the Oxford / AstraZeneca vaccine is expected to be one of the first vaccines to be submitted for regulatory approval, along with Pfizer and BioNTech’s candidate. / I hope to see positive data from BioNTech. For this I hope that we will be able to distribute the vaccine by the end of the year “.
“A COMPLETE GAME WILL BE AN EDUCATOR”
Pollard said that the protection of the developed vaccine will be around 50% at least, “I think having vaccines with significant efficacy, that is, 50, 60, 70, 80, whatever the number, that’s a huge success. That means. that, in terms of the mountain range, there will be fewer Covid-19 patients hospitalized and people receiving cancer treatment will be able to undergo chemotherapy operations. The vaccine will completely change the game, “he said.
FINDING THE VACCINE DOES NOT MEAN RETURNING TO NORMAL
However, Pollard, one of the best immunology experts in the world, said the world may not return to normal immediately after the vaccine is found. “Vaccines take time to spread. Not everyone will be able to get them in the first place. “People carrying the virus will continue to exist for a while and are very adept at transmitting Covid-19.”
CLINICAL TESTS ARE CARRIED OUT IN 3 PHASES
In order for a vaccine to be widely used, it must be tested in humans in 3 steps. In the first phase of clinical trials, the safety of the vaccine and possible side effects are studied on a small number of healthy volunteers. In the second phase, the effectiveness of the vaccine, whose reliability has been confirmed, is tested on more than 100 subjects. In the third and final stage, the same process is repeated with thousands of subjects. The whole process can take months or even years.
38 CANDIDATE VACCINES IN CLINICAL STUDY
According to data from the World Health Organization (WHO), as of 21 September 38 candidate vaccines against Covid-19 are in clinical trials and 149 candidate vaccines are in the pre-clinical evaluation phase.
9 VACCINE CANDIDATES LAST
However, against the pandemic that erupted in Wuhan, China’s Hubey province in December, 9 universities and pharmaceutical companies have reached the last point of the vaccine race. Moderna, Oxford / AstraZeneca, CanSino, SinoPharm, JohnsonJohnson, BioNTech / Pfizer, Gamaleya Institute, Sanofi / GSK and Sinofarm vaccines, now in the final phase of human experiments, are currently being tested on tens of thousands of volunteers all over the world.
DECEMBER VIRUS VACCINE IN TURKEY
Source link
